Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03775525
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:52.230026+00:00
Published At
2022-12-23T00:00:00+00:00
Record Updated At
2022-12-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Cancer", "Gastric Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer Metastatic", "Colo-rectal Cancer", "Solid Tumor", "Solid Carcinoma", "Solid Carcinoma of Stomach", "Cancer of Stomach", "Lymphoma", "Sarcoma", "Cutaneous T Cell Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Basal Cell Carcinoma", "Cutaneous T-cell Lymphoma", "Cutaneous Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-12-23"
protocolSection.identificationModule.nctId
"NCT03775525"
protocolSection.identificationModule.officialTitle
"A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Prostate Cancer Metastatic (protocolSection.conditionsModule.conditions)
  • Colo-rectal Cancer (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Solid Carcinoma (protocolSection.conditionsModule.conditions)
  • Solid Carcinoma of Stomach (protocolSection.conditionsModule.conditions)
  • Cancer of Stomach (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Sarcoma (protocolSection.conditionsModule.conditions)
  • Cutaneous T Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Cutaneous T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Cutaneous Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.